Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to viral- -40% Improvement Relative Risk c19hcq.org Li et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 37 patients in China Slower viral clearance with HCQ (not stat. sig., p=0.056) Li et al., Research Square, doi:10.21203/rs.3.rs-119202/v1 Favors HCQ Favors control
Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis
Li et al., Research Square, doi:10.21203/rs.3.rs-119202/v1 (Preprint)
Li et al., Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis, Research Square, doi:10.21203/rs.3.rs-119202/v1 (Preprint)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small retrospective database analysis of 37 late stage patients hospitalized in an intensive care center in China, not finding a significant difference in viral shedding. Pateints were all in serious condition. There was only one death however the group is not specified. Confounding by indication is likely.
time to viral-, 40.0% higher, relative time 1.40, p = 0.06, treatment 18, control 19.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 12 Jan 2021, retrospective, database analysis, China, preprint, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis Hui Li Hangzhou Red Cross Hospital Min Deng Hangzhou Red Cross Hospital Jie Wang Hangzhou Red Cross Hospital Lin Ma Hangzhou Red Cross Hospital Zheng Yang (  201411121611441@zcmu.edu.cn ) Hangzhou Red Cross Hospital Research Article Keywords: SARS-CoV-2, COVID-19, Hydroxychloroquine, Chloroquine Posted Date: January 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-119202/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Blinded Manuscript Background There is an urgent need for an effective treatment to cure patients with COVID-19 and reduce the duration of viral shedding. Methods We conducted a retrospective study using data from the electronic medical records of patients with confirmed SARS-CoV-2 infection who were hospitalized in the E1-4 intensive care center of Guanggu Hospital, Wuhan City, Hubei Province, China, from February 11, 2020, to March 23, 2020. According to the diagnostic results, the hospitalized patients were divided into the experimental group treated with hydroxychloroquine (HCQ) or chloroquine (CQ) and the control group only treated with conventional therapy without HCQ or CQ. The main outcome was the clearance rate of SARS-CoV-2. Results A total of 37 patients were evaluated. Eighteen patients were assigned to the HCQ or CQ group, and 19 were assigned to the routine treatment group. Treatment with HCQ or CQ was not associated with a difference from routine treatment in the viral shedding duration (median, 14 days vs. 10 days; hazard ratio for viral shedding, 0.393; 95% confidence interval [CI], 0.151 to 1.022; P=0.056). No significant difference in the viral shedding rate was observed between the groups at any time point (7 days, 14 days, 21 days, 28 days and the end point). Conclusion Although this is a retrospective analysis, the results suggest that treatment with HCQ or CQ had no impact on the duration of viral shedding. Keywords: SARS-CoV-2, COVID-19, Hydroxychloroquine, Chloroquine
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit